Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of rituximab-supplemented ABVD versus ABVD followed by involved-field radiotherapy in limited-stage classical Hodgkin lymphoma
2009-009431-30Phase 3Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, doxorubicin, bleomycin, vinblastine and dacarbazine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Michelangelo Foundation. Primary endpoint: Failure-free survival. Started Mar 2009; status: terminated.
02
Drugs
rituximabdoxorubicinbleomycinvinblastinedacarbazine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2009-009431-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009431-30.